Some peptide-based medications, such as semaglutide and tirzepatide products, are FDA-approved for chronic weight management under specific brand names and indications
End of a standard cycle
People with these variants might need more careful monitoring and possibly different supplements
The TGA reports a number of adverse events and other concerns received for unapproved peptide products, which include: severe allergic reactions, requiring doses of adrenaline and hospitalisation systemic inflammatory response syndrome (SIRS) (severe inflammation in the body), requiring hospital management generalised hypersensitivity symptoms such as fullbody intense itching, palpitations, pain and sweating wide ranging body side effects, including insomnia, blurred vision, extreme tiredness, flulike illness, joint pain and skin sensitivity musculoskeletal injuries, including plantar fasciitis and Achilles tendinitis, and poor product quality, including unsealed packaging from an online supplier